-
OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in gene therapy based in China, has entered into a partnership with Shenzhen Innovation Immunotechnology Co., Ltd. As per the agreement, OBiO will offer preclinical pharmaceutical research services for Shenzhen Innovation’s TCR-T cell therapy candidate, SIIT-T002.…
-
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in gene therapy, has entered into a strategic partnership with Shanghai Saierxin Biomedical Technology Co., Ltd. Under the terms of the agreement, OBiO will offer non-registered clinical trial sample preparation and testing services for Saierxin Bio’s…
